DE3613717C1 - Composition for the topical treatment of cutaneous diseases - Google Patents
Composition for the topical treatment of cutaneous diseasesInfo
- Publication number
- DE3613717C1 DE3613717C1 DE19863613717 DE3613717A DE3613717C1 DE 3613717 C1 DE3613717 C1 DE 3613717C1 DE 19863613717 DE19863613717 DE 19863613717 DE 3613717 A DE3613717 A DE 3613717A DE 3613717 C1 DE3613717 C1 DE 3613717C1
- Authority
- DE
- Germany
- Prior art keywords
- eczema
- composition
- topical treatment
- betamethasone
- resorcinol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 208000017520 skin disease Diseases 0.000 title claims abstract description 9
- 238000011282 treatment Methods 0.000 title claims abstract description 8
- 239000000203 mixture Substances 0.000 title claims abstract 4
- 230000000699 topical effect Effects 0.000 title abstract 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 229960002537 betamethasone Drugs 0.000 claims abstract description 7
- JNMRHUJNCSQMMB-UHFFFAOYSA-N sulfathiazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CS1 JNMRHUJNCSQMMB-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229960001544 sulfathiazole Drugs 0.000 claims abstract description 7
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 abstract description 17
- 239000002674 ointment Substances 0.000 abstract description 11
- 239000006071 cream Substances 0.000 abstract description 3
- 239000006210 lotion Substances 0.000 abstract description 2
- 239000007921 spray Substances 0.000 abstract description 2
- 239000012050 conventional carrier Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 229960001755 resorcinol Drugs 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 description 15
- 230000035876 healing Effects 0.000 description 6
- 241000251556 Chordata Species 0.000 description 3
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 229940070710 valerate Drugs 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 150000005207 1,3-dihydroxybenzenes Chemical class 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000949648 Angulus Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- 241000208011 Digitalis Species 0.000 description 1
- 206010064088 Nail bed inflammation Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 241000029132 Paronychia Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 241000842539 Rhagades Species 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- YUTJCNNFTOIOGT-UHFFFAOYSA-N anthracene-1,8,9-triol Chemical compound C1=CC(O)=C2C(O)=C3C(O)=CC=CC3=CC2=C1 YUTJCNNFTOIOGT-UHFFFAOYSA-N 0.000 description 1
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000002479 balanitis Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 229940037201 oris Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Die Erfindung betrifft ein Mittel zur lokalen Behandlung von Hautkrankheiten, insbesondere zur Behandlung der verschiedensten Ekzemformen, besonders von superinfizierten- entzündlichen Hautveränderungen wie Ekzema impetiginosum, Säuglingsekzeme, Ekzema seborrhoi cum capitis, besonders bei intertriginöse ekzematöse anogenitales Ekzem, Axillarekzem, sowie inguinale Entzündungen, pruritus et Ekzem Vulvae, intertriginöse Brustekzeme, superinfizierte entzündliche Akneerkrankungen bei Jugendlichen und Erwachsenen, Rosacea, intertrigenöse Ohrmuschelekzeme und Gehörgangsekzeme, Balanitis, Ekzema dyshidrotium manus et digitalis, akute mykotische Ekzeme, Dermatitis e combustione et congelatione, Mundwinkelentzündung mit Rhagaden wie angulus infectiosus oris, entzündliche Nagelbettentzündungen Paronychia.The invention relates to an agent for local treatment of skin diseases, especially for the treatment of various forms of eczema, especially super-infected inflammatory skin changes such as eczema impetiginosum, Infant eczema, eczema seborrhoi cum capitis, especially in intertriginous eczematous anogenital eczema, Axillary eczema, as well as inguinal inflammation, pruritus et eczema vulvae, intertriginous breast eczema, superinfected inflammatory acne diseases Adolescents and adults, rosacea, intertrigenous Auricular eczema and ear canal eczema, Balanitis, eczema dyshidrotium manus et digitalis, acute mycotic eczema, dermatitis e combustione et congelatione, inflammation of the mouth with rhagades like angulus infectiosus oris, inflammatory Nail bed inflammation paronychia.
Zur Bekämpfung dieser Hautkrankheiten sind bereits zahlreiche Präparate mit unterschiedlichen Wirkstoffkomponenten auf dem Markt. Es ist z. B. ein Präparat zur Behandlung von Hauterkrankungen bekannt, das das Corticosteroid Bethamethason-17-Valerat in Kombination mit dem Antibiotikum Neomycin enthält (Rote Liste 1985, Nr. 311141). Weitere Wirkstoffe - außer den üblichen Hilfs- bzw. Trägerstoffen - sind in diesem Präparat nicht enthalten. Das erfindungsgemäße Mittel hingegen weist andere Wirkstoffe - nämlich Sulfathiazol und Resorcin - in Kombination mit Bethamethason-17-Valerat auf.There are already numerous to combat these skin diseases Preparations with different active ingredient components on the market. It is Z. B. a preparation for treatment known from skin disorders, which is the corticosteroid Bethamethasone-17-valerate in combination with the Contains antibiotic neomycin (Red List 1985, No. 311141). Other active ingredients - apart from the usual auxiliaries or carriers - are not included in this preparation. The The agent according to the invention, however, has other active ingredients - namely sulfathiazole and resorcinol - in combination with Bethamethason-17-valerate.
Die Verwendung von Resorcinverbindungen zur Therapie von Hautkrankheiten geht aus der Roten Liste 1985, z. B. Nr. 31229, hervor. Das erfindungsgemäße Mittel unterscheidet sich jedoch durch die Kombination der weiteren Bestandteile von diesen bekannten Präparaten.The use of resorcinol compounds for the therapy of Skin diseases goes out of the red list 1985, z. B. No. 31229. The agent according to the invention differs However, by combining the other components of these known preparations.
Die Anwendung der bekannten Präparate zur Therapie von Hauterkrankungen führt meist zu keinen oder nur zu unbefriedigenden Heilergebnissen. In vielen Fällen verursachen die Wirkstoffe schwere Unverträglichkeiten, toxische Erscheinungen oder die Heilerfolge sind nur von kurzer Dauer; vor allem, wenn in solchen Präparaten der Wirkstoff Cignolin (1,8,9-Anthracentriol) enthalten ist.The use of known preparations for the therapy of Skin diseases usually lead to none or only unsatisfactory Healing results. In many cases the active ingredients severe intolerance, toxic Apparitions or the healing success are only from short duration; especially if in such preparations the Active ingredient cignolin (1,8,9-anthracentriol) is contained.
Aufgabe der vorliegenden Erfindung ist es, ein Mittel zur äußerlichen Behandlung von Hauterkrankungen zu schaffen, das insbesondere bei den unterschiedlichsten Ekzemformen zu guten dauerhaften Heilergebnissen bei gleichzeitig guter Verträglichkeit führt.The object of the present invention is an agent for the external treatment of skin diseases create, especially with the most varied Eczema forms contribute to good long-term healing results leads to good tolerance at the same time.
Zur Lösung dieser Aufgabe ist es erfindungsgemäß vorgesehen, daß das Mittel eine Kombination aus Resorcin, Sulfathiazol und Bethamethanon in einem geeigneten Trägermaterial enthält, wobei die Einzelbestandteile untereinander im GewichtsverhältnisTo achieve this object, the invention provides that the agent is a combination of resorcinol, Sulfathiazole and Bethamethanon in a suitable carrier contains, with the individual components among themselves in weight ratio
Resorcin60 g Sulfathiazol100 g Betamethason0,1 gResorcinol 60 g Sulfathiazole 100 g Betamethasone 0.1 g
vorliegen.are available.
Es wurde überraschenderweise gefunden, daß eine derartige Kombination sich in der Behandlung verschiedenster Ekzeme, insbesondere von superinfizierten-entzündlichen Hautveränderungen durch sehr gute Verträglichkeit auszeichnet. Die Heilwirkung ist sehr gut. Es wird eine dauerhafte Heilung erzielt.It has surprisingly been found that such Combination of different treatments Eczema, especially from super-infected-inflammatory ones Skin changes are characterized by very good tolerance. The healing effect is very good. It will be one permanent healing achieved.
Das Mittel kann als Lotion, Creme, Salbe, Spray oder dgl. zur Anwendung kommen.The agent can be used as a lotion, cream, ointment, spray or Like. Are used.
Die erfindungsgemäße Wirkstoffkombination wurde insbesondere in Form von Creme und Salbe an einer großen Zahl von Patienten, die an Ekzemen litten, getestet. Als Salbengrundlage bewährten sich dabei besonders Unguentum Cordes und Unguentum Doritin. Unguentum Doritin wird von der Haut sehr leicht aufgenommen und ist kosmetisch auch für die Gesichtshaut geeignet. Unguentum Cordes wird bevorzugt bei trockenen schuppigen Hautveränderungen als Grundlage angewandt. Hervorragende Wirkungen zeigen Salben, in denen die Wirkstoffkombination Resorcin-Sulfathiazol-Betamethason in einer Konzentration von 10 bis 20 Gew.-%, vorzugsweise 60 Gew.-%, enthalten ist. The combination of active substances according to the invention was especially in the form of cream and ointment on a large Number of patients with eczema tested. They have proven particularly useful as an ointment base Unguentum Cordes and Unguentum Doritin. Unguentum Doritin is very easily absorbed by the skin cosmetically also suitable for the facial skin. Unguentum Cordes is preferred for dry scaly Skin changes applied as a basis. Outstanding Effects show ointments in which the Combination of active ingredients resorcinol-sulfathiazole-betamethasone in a concentration of 10 to 20% by weight, preferably 60 wt .-% is included.
Bei den Testpersonen wurde bei niedriger Dosierung eine sehr gute Heilwirkung und gute Verträglichkeit beobachtet, die aus der optimalen Wirkstoff-Kombination resultiert. Nebenwirkungen, die bei Anwendung von anderen Corticosteroid-Präparaten auftreten können wie Teleangiectasie, Atrophie oder Purpura, treten auch bei längerer Anwendung des erfindungsgemäßen Mittels nicht auf.A low dose was used in the test subjects very good healing effects and good tolerability observed, which results from the optimal combination of active ingredients. Side effects when using others Corticosteroid supplements can occur like Telangiectasia, atrophy, or purpura also occur prolonged use of the agent according to the invention not on.
Die Erfindung wird durch die folgenden Beispiele näher erläutert:The invention is illustrated by the following examples explains:
Resorcin60 g Sulfathiazol100 g Betamethason0,1 g (Bethametason)17-Valerat) Unguentum Doritin, ad1000 gResorcinol 60 g Sulfathiazole 100 g Betamethasone 0.1 g (Bethametasone) 17-valerate) Unguentum Doritin, ad1000 g
Resorcin15 g Sulfathiazol25 g Betamethason25 mg Unguentum Cordes, ad250 gResorcinol 15 g Sulfathiazole 25 g Betamethasone 25 mg Unguentum Cordes, ad250 g
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19863613717 DE3613717C1 (en) | 1986-04-23 | 1986-04-23 | Composition for the topical treatment of cutaneous diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19863613717 DE3613717C1 (en) | 1986-04-23 | 1986-04-23 | Composition for the topical treatment of cutaneous diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3613717C1 true DE3613717C1 (en) | 1987-09-03 |
Family
ID=6299330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19863613717 Expired DE3613717C1 (en) | 1986-04-23 | 1986-04-23 | Composition for the topical treatment of cutaneous diseases |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE3613717C1 (en) |
-
1986
- 1986-04-23 DE DE19863613717 patent/DE3613717C1/en not_active Expired
Non-Patent Citations (1)
| Title |
|---|
| Rote Liste Ed. Cantor, Aulendorf 1985, Nr. 31141 u. 31229 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69520041T2 (en) | MEDICINAL PRODUCTS BASED ON A SYNERGISTIC MIXTURE OF METRONIDAZOLE AND CLINAMICIN | |
| DE3882848T2 (en) | BASIC COSMETIC PREPARATION WITH MEDICAL PROPERTIES. | |
| EP0152106B1 (en) | Antirheumatic compositions | |
| DE2818553A1 (en) | COMPOSITION FOR THE TREATMENT OF PROLIFERATIVE SKIN DISEASES | |
| EP0367103B1 (en) | Topical ointment | |
| DE2131441C3 (en) | Skin bleach | |
| DE3302739A1 (en) | OXIDATION STABLE MEDIUM | |
| DE69212610T2 (en) | Composition for the treatment of steroid-induced skin atrophy containing a salt of a C3-7 alpha-hydroxy-carboxylic acid | |
| DE19804376B4 (en) | Lipid mixtures and their use | |
| EP0467116B1 (en) | Dermatological compositions containing cis-urocanic acid | |
| DE2609575C2 (en) | Cosmetic preparation | |
| EP0336000B1 (en) | Ambiphilic cream | |
| DE3613717C1 (en) | Composition for the topical treatment of cutaneous diseases | |
| EP0342524B1 (en) | Medicine for treating mycotic, microbial and other tissue damaging and pathological manifestations and deformations of tissue | |
| DE2912438C2 (en) | ||
| DE19904801A1 (en) | Agent containing urea, sulfur and Calendula extract, useful for topical treatment of skin disorders, especially neurodermatitis | |
| DE3811272A1 (en) | METHOD FOR SETTING UP A PHARMACEUTICAL COMPOSITION, PREFERABLY A LOTION | |
| DE60213794T2 (en) | SKIN PREPARATION | |
| DE2338323C2 (en) | Antiseptic aqueous preparation for the treatment of the skin | |
| DE2729888C2 (en) | Make-up removal lotion for the eyes | |
| DE60123132T2 (en) | LIPOSOME FORMULATION WITH CLOBETASOL PROPIONATE | |
| US3019162A (en) | Cinchophen-hydrocortisone topical compositions | |
| WO1996012504A1 (en) | Oil-in-water formulation for topical application | |
| DE1922192C2 (en) | Compositions for the treatment of trophic disorders of the skin and processes for their preparation | |
| DE3280419T2 (en) | MEDICAL PREPARATION FOR TREATING SKIN DISEASES. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8100 | Publication of the examined application without publication of unexamined application | ||
| D1 | Grant (no unexamined application published) patent law 81 | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |